We report six cases of locally advanced, non-metastatic gastric cancer with elevated AFP, all of which demonstrated a favorable response and were well tolerated by the patients after the use of immune checkpoint inhibitors and neoadjuvant chemotherapy. This study suggests that programmed death receptor 1(PD-1) checkpoint inhibitors plus chemotherapy can benefit patients with AFPGC and provide a reference for the treatment of patients with AFPGC, and its mechanism of action deserves further study.
Liu et al. (Mon,) studied this question.